Lesson plan
Fedratinib
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = | image = Fedratinib.svg | image_class = skin-invert-image | width = 275 | alt = | caption = | pronounce = | tradename = Inrebic | Drugs.com = | MedlinePlus = | DailyMedID = Inrebic | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = EJ02 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number_Ref = | CAS_number = 936091-26-8 | CAS_supplemental = | PubChem = 16722836 | PubChemSubstance = | IUPHAR_ligand = 5716 | DrugBank = DB12500 | ChemSpiderID = 17626393 | UNII = 6L1XP550I6 | KEGG = D10630 | ChEBI = 91408 | ChEMBL = 1287853 | NIAID_ChemDB = | PDB_ligand = | synonyms = SAR302503; TG101348 | IUPAC_name = N-tert -butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide | C=…
Article summary
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = | image = Fedratinib.svg | image_class = skin-invert-image | width = 275 | alt = | caption = | pronounce = | tradename = Inrebic | Drugs.com = | MedlinePlus = | DailyMedID = Inrebic | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = EJ02 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number_Ref = | CAS_number = 936091-26-8 | CAS_supplemental = | PubChem = 16722836 | PubChemSubstance = | IUPHAR_ligand = 5716 | DrugBank = DB12500 | ChemSpiderID = 17626393 | UNII = 6L1XP550I6 | KEGG = D10630 | ChEBI = 91408 | ChEMBL = 1287853 | NIAID_ChemDB = | PDB_ligand = | synonyms = SAR302503; TG101348 | IUPAC_name = N-tert -butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide | C=…
Key claims
- publication date: 2011 — source: Wikipedia, revision 1348510868, retrieved 2026-10-20 · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the publication date is "2011". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia, “Fedratinib”, revision 1348510868, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1348510868
Key claims and bibliography are generated from the same tracked claims and sources as the article page.